Research Article
Effectiveness and Safety of Low Dose of Tenofovir Disoproxil Fumarate in Malagasy Patients with Chronic Hepatitis B
Table 2
Virological, biochemical, and clinical response after low-dose TDF in overall population, viraemic, and nonviraemic patients at baseline.
| Variables | 3 months, (%) | 6 months, (%) | 12 months, (%) |
| Overall response () | | | | CVR | 36 (80) | 41 (91.1) | 43 (95.6) | PVR (ADN-VHB 20–2000 UI/mL) | 5 (11.1) | 3 (6.7) | 2 (4.4) | UI/mL | 4 (8.9) | 1 (2.2) | 0 (0) | ALT normalization | 29 (64.4) | 39 (86.7) | 45 (100) | HCC development | 0 (0) | 0 (0) | 0 (0) | Decompensation of cirrhosis () | 0 (0) | 0 (0) | 0 (0) | Viraemic patients at baseline () | | | | CVR | 26/35 (74.3) | 31/35 (88.6) | 33/35 (94.3) | PVR (ADN-VHB 20–2000 UI/mL) | 5/35 (14.3) | 3/35 (8.6) | 2/35 (5.7) | UI/mL | 4/35 (11.4) | 1/35 (2.8) | 0/35 (0) | Nonviraemic patients at baseline () | | | | CVR | 10/10 (100) | 10/10 (100) | 10/10 (100) | Elevated ALT at baseline () | | | | ALT normalization | 0/16 (0) | 10/16 (62.5) | 16/16 (100) |
|
|
CVR: complete virological response; PVR: partial virological response; DNA: deoxyribonucleic acid; HBV: hepatitis B virus; ALT: alanine aminotransferase; HCC: hepatocellular carcinoma.
|